Results of the Austrian National Lung Cancer Audit

Otto C Burghuber, Klaus Kirchbacher, Andrea Mohn-Staudner, Maximilian Hochmair, Marie-Kathrin Breyer, Michael Studnicka, Michael Rolf Mueller, Petra Feurstein, Andrea Schrott, Bernd Lamprecht, Josef Eckmayr, Friedrich Renner, Josef Bolitschek, Wolfgang Pohl, Peter Schenk, Peter Errhalt, Peter Cerkl, Bernhard Baumgartner, Meinhard Kneussl, Sylvia Hartl

Research output: Journal article (peer-reviewed)Journal article

4 Citations (Scopus)


OBJECTIVES: The Austrian Lung Cancer Audit (ALCA) is a pilot study to evaluate clinical and organizational factors related to lung cancer care across Austria.

MATERIALS AND METHODS: The ALCA is a prospective, observational, noninterventional cohort study conducted in 17 departments in Austria between September 2013 and March 2015. Participating departments were selected based on an annual case load of >50 patients with lung cancer.

RESULTS: The ALCA included 745 patients, representing 50.5% of all newly diagnosed cancer cases during that time period. In 75.8% of patients, diagnosis was based on histology, and in 24.2% on cytology; 83.1% had non-small-cell lung cancer, 16.9% small-cell lung cancer; and only 4.6% had to be classified as not otherwise specified cancers. The median time elapsed between first presentation at hospital and diagnosis was 8 days (interquartile range [IQR]: 4-15; range: 0-132); between diagnosis and start of treatment it was 15 days for chemotherapy (IQR: 9-27; range: 0-83), 21 days (IQR: 10-35; range: 0-69) for radiotherapy, and 24 days (IQR: 11-36; range: 0-138) for surgery, respectively. In 150 patients undergoing surgical treatment, only 3 (2.0%; n = 147, 3 missings) were seen with postoperative restaging indicating unjustified surgery. One-year follow-up data were available for 723 patients, indicating excellent 49.8% survival; however, a wide range of survival between departments (range: 37.8-66.7) was seen.

CONCLUSIONS: The ALCA conducted in high case load departments indicated management of lung cancer in accordance with international guidelines, and overall excellent 1-year survival.

Original languageEnglish
Pages (from-to)1179554920950548
JournalClinical Medicine Insights: Oncology
Publication statusPublished - 2020


Dive into the research topics of 'Results of the Austrian National Lung Cancer Audit'. Together they form a unique fingerprint.

Cite this